HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Triclocarbon Category I Antibacterial Efficacy Supported By Bayer Studies

This article was originally published in The Rose Sheet

Executive Summary

Triclocarbon in concentrations up to 1.5% should be included as a Category I active ingredient in the healthcare antiseptic tentative final monograph, Bayer says in a 1Dec. 28 citizen petition to FDA

You may also be interested in...



Triclosan Antiseptic Category I Status Requested By CIBA

FDA should consider new safety data supporting Category I (safe and effective) status for triclosan in the OTC Tentative Final Monograph for Health Care Antiseptic Drug Products, CIBA Specialty Chemicals and an alliance of six triclosan manufacturers/ marketers state in a Sept. 13 citizen petition.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009950

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel